相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis
H. Landau et al.
LEUKEMIA (2013)
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
Joseph R. Mikhael et al.
BLOOD (2012)
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
Christopher P. Venner et al.
BLOOD (2012)
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
Shaji K. Kumar et al.
BLOOD (2012)
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
Shaji Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Cancer-testis antigen expression and immunogenicity in AL amyloidosis
M. A. Rosenzweig et al.
BLOOD CANCER JOURNAL (2012)
Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management
Morie A. Gertz
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis
H. Landau et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2011)
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
Maria Teresa Cibeira et al.
BLOOD (2011)
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
Donna E. Reece et al.
BLOOD (2011)
Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis
Ashutosh D. Wechalekar et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Amyloidosis: Pathogenesis and New Therapeutic Options
Giampaolo Merlini et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
Angela Dispenzieri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
The 4th International Symposium on Alzheimer's Disease and Related Disorders in the Middle East, October 26-28, 2007, Athens, Greece
Changiz Geula et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2010)
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2010)
Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis
Vaishali Sanchorawala et al.
BLOOD (2010)
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
Philippe Moreau et al.
BLOOD (2010)
Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis
Julian D. Gillmore et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Currents Concepts on the Immunopathology of Amyloidosis
Anupama Bhat et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2010)
Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
Efstathios Kastritis et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report
Morie A. Gertz et al.
LEUKEMIA & LYMPHOMA (2010)
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
Karl Bodin et al.
NATURE (2010)
Frequencies and Types of Arrhythmias in Patients With Systemic Light-Chain Amyloidosis With Cardiac Involvement Undergoing Stem Cell Transplantation on Telemetry Monitoring
Yuliya B. Goldsmith et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
The NKG2D ligand ULBP4 binds to TCRγ9/δ2 and induces cytotoxicity to tumor cells through both TCRγδ and NKG2D
Yan Kong et al.
BLOOD (2009)
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
Donna E. Reece et al.
BLOOD (2009)
Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens
Julie A. Vrana et al.
BLOOD (2009)
Thromboembolic events with lenalidomide-based therapy for multiple myeloma
Smitha Patiyil Menon et al.
CANCER (2008)
Azotemia associated with use of lenalidomide in plasma cell dyscrasias
Eric D. Batts et al.
LEUKEMIA & LYMPHOMA (2008)
Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis
Morie Gertz et al.
LEUKEMIA & LYMPHOMA (2008)
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Recovery, viability and clinical toxicity of thawed and washed haematopoietic progenitor cells:: analysis of 952 autologous peripheral blood stem cell transplantations
E. Fois et al.
BONE MARROW TRANSPLANTATION (2007)
Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response
Morie A. Gertz et al.
HAEMATOLOGICA (2007)
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone ± thalidomide for systemic light-chain amyloidosis:: results of a phase II trial
Adam D. Cohen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
Arnaud Jaccard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2007)
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
Vaishali Sanchorawala et al.
BLOOD (2007)
Transplantation for amyloidosis
Morie A. Gertz et al.
CURRENT OPINION IN ONCOLOGY (2007)
Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins
RL Comenzo et al.
BLOOD (2006)
Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis
T Imamura et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis:: a report from the European Group for Blood and Marrow Transplantation
SP Schönland et al.
BLOOD (2006)
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
MA Gertz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation
AA Jungbluth et al.
BLOOD (2005)
Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis
B Oran et al.
BONE MARROW TRANSPLANTATION (2005)
Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
G Palladini et al.
BLOOD (2004)
The role of depletion of dimethyl sulfoxide before autografting:: On hematologic recovery, side effects, and toxicity
R Syme et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2004)
High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study
M Skinner et al.
ANNALS OF INTERNAL MEDICINE (2004)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate
MA Gertz et al.
BONE MARROW TRANSPLANTATION (2004)
Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628
MV Dhodapkar et al.
BLOOD (2004)
Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan
Y Kawai et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2004)
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis
A Dispenzieri et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2003)
Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis
DC Seldin et al.
CLINICAL LYMPHOMA (2003)
Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies
A Solomon et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2003)
Autologous stem cell transplantation for primary systemic amyloidosis
RL Comenzo et al.
BLOOD (2002)
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.
HJ Lachmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis
V Sanchorawala et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
MB Pepys et al.
NATURE (2002)
Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL)
MA Gertz et al.
BONE MARROW TRANSPLANTATION (2000)
Antibody-mediated resolution of light chain-associated amyloid deposits
R Hrncic et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
分享论文
